The E2F family regulates cell cycle progression, DNA replication, and apoptosis. Antibodies against these proteins are critical for studying their roles in tumorigenesis and drug resistance.
E2F antibodies are pivotal in elucidating the family’s role in cancer progression and therapy resistance.
Cell Cycle Regulation: E2F1/2/3 drive G1/S transition and inhibit apoptosis, promoting tumor growth .
DNA Damage Response: E2F8 suppresses DNA repair pathways, enhancing genomic instability .
Drug Resistance: Overexpression of E2F2/3/8 correlates with chemotherapy resistance, suggesting their role in multidrug resistance .
Antibodies are rigorously tested for specificity and sensitivity:
E2F antibodies are tools for developing targeted therapies:
This antibody targets E2FE, an inhibitor of E2F-dependent gene expression activation. E2FE specifically binds to the E2 recognition site without interacting with DP proteins, thereby preventing transcriptional activation by E2F/DP heterodimers. Its function includes controlling the timing of endocycle onset and inhibiting endoreduplication.
E2FE's role is supported by the following research findings: